Updates in the management of hepatocellular carcinoma.

摘要: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death, and its increasing incidence worldwide for concern. Fortunately, advances in diagnostic therapeutic approaches have contributed to earlier detection treatment. As cancer epidemiology studies continue elucidate the natural history liver diseases, greater understanding HCC has led improved risk stratification enrollment high-risk patients screening surveillance programs. Improved survival rates among also reflect significant available treatment options. Advances surgical techniques are pushing boundaries resection localized disease, progress field transplantation refinements listing criteria post-transplantation outcomes. The evolving locoregional therapies—including percutaneous ablation transarterial chemoembolization—continues provide novel options that can be used place of, or addition to, approaches. Recent systemic multikinase inhibitor therapies demonstrated benefits advanced-stage these show promise as adjuvant treatments earlier-stage disease. This article provides an update on management HCC, with focus revised guidelines in-depth discussion emerging therapies.